Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
作者信息
Minor David R, Puzanov Igor, Callahan Margaret K, Hug Bruce A, Hoos Axel
机构信息
California Pacific Center for Melanoma Research and Treatment, San Francisco, CA, USA.
Division of Hematology-Oncology, Vanderbilt University, Nashville, TN, USA.
出版信息
Pigment Cell Melanoma Res. 2015 Sep;28(5):611-2. doi: 10.1111/pcmr.12383. Epub 2015 Jun 23.
Abstract
摘要
相似文献
1
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
Pigment Cell Melanoma Res. 2015 Sep;28(5):611-2. doi: 10.1111/pcmr.12383. Epub 2015 Jun 23.
2
Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
Acta Oncol. 2018 Aug;57(8):1131-1133. doi: 10.1080/0284186X.2018.1449251. Epub 2018 Mar 11.
3
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
4
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Oncotarget. 2016 Aug 30;7(35):56619-56627. doi: 10.18632/oncotarget.10651.
5
Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
Eur Heart J. 2017 Jul 14;38(27):2151. doi: 10.1093/eurheartj/ehx133.
6
Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
J Cutan Med Surg. 2017 Jan/Feb;21(1):54-59. doi: 10.1177/1203475416670368. Epub 2016 Sep 22.
7
[Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
Ophthalmologe. 2016 Oct;113(10):861-863. doi: 10.1007/s00347-016-0226-8.
8
Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy.
J Dtsch Dermatol Ges. 2020 Feb;18(2):136-139. doi: 10.1111/ddg.13991. Epub 2019 Dec 9.
9
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Eur J Cancer. 2015 May;51(7):833-40. doi: 10.1016/j.ejca.2015.03.004. Epub 2015 Mar 17.
10
Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
Melanoma Res. 2020 Jun;30(3):317-320. doi: 10.1097/CMR.0000000000000649.
引用本文的文献
1
Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Pharmaceuticals (Basel). 2025 Aug 21;18(8):1235. doi: 10.3390/ph18081235.
2
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.
Cancer Drug Resist. 2024 Oct 31;7:42. doi: 10.20517/cdr.2024.54. eCollection 2024.
3
Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.
Mol Ther Nucleic Acids. 2024 Jul 19;35(3):102283. doi: 10.1016/j.omtn.2024.102283. eCollection 2024 Sep 10.
4
Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies.
Chem Res Toxicol. 2024 Jul 15;37(7):1086-1103. doi: 10.1021/acs.chemrestox.4c00067. Epub 2024 Jun 24.
5
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation.
Nat Commun. 2024 Mar 9;15(1):2163. doi: 10.1038/s41467-024-46422-5.
6
Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma.
Int J Mol Sci. 2024 Jan 31;25(3):1725. doi: 10.3390/ijms25031725.
7
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Nat Rev Immunol. 2024 Jun;24(6):399-416. doi: 10.1038/s41577-023-00973-8. Epub 2023 Dec 6.
8
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
J Immunother Cancer. 2023 Jul;11(7). doi: 10.1136/jitc-2023-006821.
9
Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Cancer Metastasis Rev. 2023 Jun;42(2):481-505. doi: 10.1007/s10555-023-10097-z. Epub 2023 Apr 6.
10
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.
Curr Oncol Rep. 2023 Jun;25(6):623-634. doi: 10.1007/s11912-023-01402-8. Epub 2023 Mar 30.
本文引用的文献
1
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
2
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
3
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
J Clin Oncol. 2014 Jul 20;32(21):2248-54. doi: 10.1200/JCO.2013.52.1377. Epub 2014 Jun 23.
4
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.
Cancer Immunol Res. 2014 Jan;2(1):70-9. doi: 10.1158/2326-6066.CIR-13-0160.
5
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
6
Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.
7
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
8
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
J Exp Med. 2006 Jul 10;203(7):1651-6. doi: 10.1084/jem.20051848. Epub 2006 Jun 26.
9
Claudins regulate the intestinal barrier in response to immune mediators.
Gastroenterology. 2000 Jun;118(6):1001-11. doi: 10.1016/s0016-5085(00)70351-9.
Zotero 插件